Latest Entries
New Instrument Provides Instant Results

New Instrument Provides Instant Results

The New England Eye Center sees nearly 10,000 patients diagnosed with corneal disease every year. It can take anywhere from a few days to a few weeks to diagnose and begin treatment for corneal infections. The standard diagnostic procedure involves taking a biopsy of corneal tissue. Then waiting for the results from a pathologist. What … Continue reading

Success Story: FDA Approved Drug Treatment for AMD

Embed from Getty Images An FDA Approved Drug Treatment For Age Related Macular Degeneration (AMD). Studies undertaken by Massachusetts Eye and Ear Infirmary researchers led to the first FDA-approved drug treatment for neovascular AMD: photodynamic therapy (PDT) with Visudyne®, a combination laser/drug therapy. Now over a decade in use, Visudyne® was a revolution in patient … Continue reading

Success Story: New Gene Therapy for Dry AMD

Success Story: New Gene Therapy for Dry AMD

With support from MLERFi, researchers at Tufts University School of Medicine have developed a new gene therapy that will be tested in human patients In 2016. Specifically, this therapy will target the ‘dry’ form of AMD that currently accounts for 90% of AMD patients, none of whom can be currently treated. This gene therapy uses … Continue reading

Success Story: Exciting Discoveries re: Two Rare Children’s Blinding Diseases

Success Story: Exciting Discoveries re: Two Rare Children’s Blinding Diseases

Researchers at Children’s Hospital have made exciting discoveries in two related rare children’s blinding diseases: Familial Exudative VitreoRetinopathy (FEVR) and Norrie disease. Both diseases share similar symptoms of abnormal leaky blood vessels in the eye that can steal a child’s eyesight early in life. The research team found that defective genes damage junctions in the … Continue reading

Success Story: A Retinal Prosthesis

Success Story: A Retinal Prosthesis

MLERFi and the Massachusetts Eye and Ear Infirmary have been committed partners for more than two decades in pursuit of the most ambitious technological innovations to date―developing a retinal prosthesis designed to restore useful vision to patients who are blind from age-related macular degeneration and retinitis pigmentosa. The primary goal of the prosthesis is to … Continue reading